La catena delle opzioni mostra i dati chiave delle opzioni azionarie di SILO Pharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per SILO Pharma..

SILO Pharma (NASDAQ:SILO) Azioni, Catena delle Opzioni

SILO Pharma

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

SILO Pharma Inc

Silo Wellness Inc

DA Davidson analyst Keegan Cox maintains Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) with a Buy and maintains $7 price target.

News

Price Target

Analyst Ratings

FNKO

DA Davidson Maintains Buy on Funko, Maintains $7 Price Target

WIIM

CANF

Can-Fite Biopharma shares are trading lower after the company announced a $5 million ADS public offering.

SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) shares are trading higher Monday after the company provided 2025 fiscal-year and <a href="https://www.benzinga.com/node/46655382">second-quarter guidance</a>.
What To Know: SES guided second-quarter revenue of $3.5 million, which would bring its total revenue for the first half of 2025 to $9.3 million. The company affirmed its full-year 2025 revenue guidance of $15 million to $25 million and posted a gross margin of 74% for the quarter.
Operating cash use fell 51% year-over-year to $10.8 million, and the company ended the quarter with $229 million in liquidity and no debt.
SES also announced a deal to acquire UZ Energy, which it expects to generate additional revenue in 2025.
 "We continued our path to profitability with revenue of $3.5 million during the second quarter," said Founder and CEO Qichao Hu. "We are deploying a nominal amount of our excess liquidity to pursue what we view as a tremendous opportunity to accelerate our platform strategy in the global energy storage market."
The company plans to release its full second-quarter results after market close on August 4.
\Related Link: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46666781/wall-street-gets-bullish-new-analyst-targets-signal-more-upside-ahead-for-ge-aerospace">Wall Street Gets Bullish: New Analyst Targets Signal More Upside Ahead For GE Aerospace</a>
SES Price Action: At the time of writing, SES shares are trading 17.8% higher at $1.39, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Image: This illustration was generated using artificial intelligence via Midjourney.

Movers

SES AI Stock Is Moving Higher Monday: What's Going On?

Raymond James analyst Andrew Marok maintains Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Outperform and raises the price target from $490 to $570.

MSFT

Raymond James Maintains Outperform on Microsoft, Raises Price Target to $570

Compass Point analyst Casey Alexander maintains Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) with a Neutral and raises the price target from $432 to $490.

KNSL

Compass Point Maintains Neutral on Kinsale Cap Gr, Raises Price Target to $490

Raymond James analyst Josh Beck maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Strong Buy and raises the price target from $150 to $175.

RDDT

Raymond James Maintains Strong Buy on Reddit, Raises Price Target to $175

Macro Economic Events

Politics

Global

Economics

General

Reuters Reports U.S.-China Trade Talks Have Concluded For The Day, Says Source Familiar With The Talks

Canaccord Genuity analyst Maria Ripps maintains Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) with a Buy and raises the price target from $58 to $70.

Canaccord Genuity Maintains Buy on Wayfair, Raises Price Target to $70

Canaccord Genuity analyst Maria Ripps maintains Life360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIF#NASDAQ">LIF</a>) with a Buy and raises the price target from $75 to $86.

Canaccord Genuity Maintains Buy on Life360, Raises Price Target to $86

Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is gearing up for a significant rebound in the second half of fiscal 2025, driven by the highly anticipated launch of new product cycles, including a &#8216;slim&#8217; iPhone, and sustained momentum in its lucrative Services division, even as it contends with rising tariff costs and ongoing regulatory challenges.
On Monday, Bank of America Securities analyst Wamsi Mohan <a target="_blank" href="https://www.benzinga.com/quote/AAPL/analyst-ratings" rel="noreferrer noopener">reaffirmed a Buy rating</a> on Apple, maintaining a price forecast of $235.
As Apple prepares to release its fiscal third-quarter earnings on July 31, investor sentiment, as noted by Mohan, remains somewhat subdued.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46636565/apple-faces-existential-threat-if-it-fails-to-act-on-genai" rel="noreferrer noopener">Apple Faces Existential Threat If It Fails To Act On GenAI</a>
Key concerns include escalating tariff-related costs, scrutiny from the Department of Justice regarding Google&#8217;s traffic acquisition cost (TAC) payments, ongoing headwinds for the App Store, and the perceived slow pace of Apple&#8217;s advancements in artificial intelligence.
Nevertheless, the impending earnings call is expected to shift focus towards gross margin trends and the projected recovery trajectory fueled by forthcoming product launches.
For fiscal third-quarter 2025, Mohan projects revenue of $90.2 billion and earnings per share (EPS) of $1.45, figures that slightly surpass consensus Street estimates of $89.3 billion and $1.43, respectively.
The analyst anticipates a gross margin of approximately 46.1%, aligning with Apple&#8217;s guidance midpoint, despite the absorption of an estimated $900 million in tariff-related costs.
Looking ahead to the fourth quarter, projections indicate revenue of $99.5 billion and EPS of $1.66, largely in line with Street expectations.
While gross margin is projected to dip to 45% due to an additional $1 billion in tariff impact, Mohan views this quarter as a trough, with margins expected to improve heading into fiscal 2026.
Mohan noted that a key driver of this expected rebound is the highly anticipated &#8220;slim&#8221; iPhone, potentially branded as the iPhone &#8220;Air,&#8221; which Apple is likely to launch in fall 2025.
The analyst said that this model, expected to replace last year&#8217;s Plus version, will reportedly have a 6.6-inch display, measure just 6mm thick, and carry a price tag $100 higher than the Plus.
He noted that the shift in product mix toward higher average selling prices (ASP) is anticipated to drive gross margin expansion and boost replacement rates. Mohan modeled stronger iPhone sales in the September and December quarters on the back of this launch.
On the Mac front, Apple is expected to benefit from the March launch of the new MacBook Air featuring the M4 chip, which provides improved performance at a reduced entry price of $999, or $100 lower than its predecessor, the analyst noted.
He said this is expected to drive better-than-seasonal Mac revenue in the June and December quarters. Similarly, Mohan said the iPad segment could receive a boost from the expected fall launch of iPad Pro models equipped with the M5 chip. The analyst anticipates revenue growth in iPads driven by higher ASPs and product upgrades.
Apple&#8217;s Services segment continues to show steady growth, Mohan noted. For the third quarter, he expects Services revenue of $27.1 billion, up 2% quarter-over-quarter and 12% year-over-year.
Substantial year-over-year gains are projected across the App Store (+12%), Licensing (+18%), Subscriptions (+9%), and Apple Pay (+18%), as per the analyst.
For the fourth quarter, Services are projected to rise another 3% sequentially to $28 billion, again marking a 12% annual increase, with Licensing and Apple Pay both expected to grow over 20% year-over-year, Mohan noted.
Mohan slightly raised estimates for the full fiscal year 2025. Revenue is now forecast at $409 billion (up from $408 billion), and EPS at $7.15 (up from $7.13). The price forecast remains $235, based on a 29x multiple of fiscal 2026 estimated EPS of $8.20.
While Apple faces near-term margin pressure and regulatory noise, Mohan noted upside potential in new product cycles, improving Services momentum, and ASP-driven gross margin recovery, positioning the stock for renewed strength in the back half of the year.
AAPL&nbsp;Price Action:&nbsp;Apple stock is trading higher by 0.10% to $214.06 at last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46656199/pony-ai-gets-green-light-for-driverless-robotaxis-in-shanghais-pudong" target="_blank" rel="noreferrer noopener">Pony.ai Gets Green Light For Driverless Robotaxis In Shanghai&#8217;s Pudong</a></li>
</ul>
Image via Shutterstock

Reiteration

Tech

Trading Ideas

AAPL

Can Apple's Slim iPhone And Cheaper Macs Reverse The 2025 Stock Slump?

Blue Gold shares are trading lower after the company announced that it's making advancements with its Mampon acquisition. Additionally, the company provided annual gold production targets for the next five years.

Canaccord Genuity analyst Maria Ripps maintains Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Buy and raises the price target from $62 to $68.

ETSY

Canaccord Genuity Maintains Buy on Etsy, Raises Price Target to $68

Stifel analyst Stephen Gengaro maintains Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) with a Buy and lowers the price target from $20 to $19.

LBRT

Stifel Maintains Buy on Liberty Energy, Lowers Price Target to $19

Stifel analyst Brad Reback maintains Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Buy and raises the price target from $500 to $550.

Stifel Maintains Buy on Microsoft, Raises Price Target to $550

Canaccord Genuity analyst Sumant Kulkarni maintains ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with a Buy and lowers the price target from $12 to $11.

ATAI

Canaccord Genuity Maintains Buy on ATAI Life Sciences, Lowers Price Target to $11

TECK

Teck Resources shares are trading higher. Benchmark maintained a Buy rating on the stock.

Booz Allen Hamilton shares are trading lower. Stifel maintained a Hold rating on the stock while JP Morgan maintained an Underweight rating.

ESLOF

ESLOY

During Conf Call, EssilorLuxottica CFO Reportedly Says Group Working On Diversification Of Supply Chain And Price Adjustments To Mitigate Impact Of U.S. Tariffs; Group Increased Prices By Mid-Single Digit In U.S., But Effect Will Be Seen Mostly In Second Half; CEO Reportedly Says Group Could Further Increase SmartGlass Production Capacity Over 10B Pieces We Expect Now; We Expect Sales Of Meta SmartGlasses To Accelerate, Forecast Is Really Higher Than Before

Texas Instruments shares are trading higher after Wolfe Research upgraded the stock from Peer Perform to Outperform and announced a price target of $230.

MicroVision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) stock had a brief uptick before going down on Monday after the company announced that its <a href="https://www.benzinga.com/pressreleases/25/07/ac46658667/microvision-movia-lidar-now-supported-on-nvidia-drive-agx-enabling-advanced-perception-enhanced-s" target="_blank" rel="noreferrer noopener">MOVIA lidar system</a> is now officially supported on the NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) DRIVE AGX platform, a key development aimed at accelerating the adoption of its perception-enhanced lidar technology within the autonomous driving market.
MicroVision generates most of its revenue by developing and licensing its laser beam scanning (LBS) technology, targeting automotive and industrial lidar applications. The company also earns income from selling augmented reality (AR) and consumer lidar modules.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44479292/microvisions-strategic-moves-and-new-cto-drive-analyst-confidence-but-challenges-remain-in-q4" target="_blank" rel="noreferrer noopener">MicroVision&#8217;s Strategic Moves And New CTO Drive Analyst Confidence, But Challenges Remain In Q4</a>
The Nvidia DRIVE AGX platform is a high-performance, scalable, and energy-efficient AI computing system designed to handle the complex workloads required for autonomous vehicles.
By integrating MOVIA via a plugin driver, MicroVision enables automotive OEMs and partners to access rich, processed point cloud data directly from the lidar sensor, reducing the need for additional computing and simplifying system architecture.
MicroVision's Chief Technology Officer Glen DeVos said the integration will allow faster deployment of its lidar solutions in advanced driver-assistance systems (ADAS) and full autonomy platforms. He highlighted that MicroVision's MOVIA sensors combine onboard perception capabilities with cost efficiency, making them highly competitive in commercial trucking and high-volume automotive applications.
DeVos also noted the industrialized MOVIA L sensor is tailored for commercial trucking fleets. At the same time, the upcoming MOVIA S is expected to deliver high performance at a lower price point for mass-market vehicles. The company views this collaboration with Nvidia as a significant step in accelerating its entry into the global automotive market, while continuing to explore broader industrial applications for its perception technology.
MicroVision stock gained 16% year-to-date, gaining close to 30% in the last three months. despite missing the revenue analyst consensus in the past three quarters. It missed the EPS consensus in the last two quarters.
MVIS, NVDA Price Actions: MicroVision stock is down 5.77% at $1.23; Nvidia is up 0.96% at $175.17.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/small-cap/25/07/46614701/mullen-automotive-rebrands-to-bollinger-innovations" target="_blank" rel="noreferrer noopener">Mullen Automotive Rebrands To Bollinger Innovations</a></li>
</ul>
Courtesy: MicroVision

MVIS

NVDA

MicroVision Tech On Nvidia Platform — What's Going On?

Press Releases

Silo Pharma Announces Closing of $2 Million Public Offering

Health Care

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Legal

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Silo Pharma Enters into Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

HOTH

SILO

Aditxt

Apollomics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Azitra

Bone Biologics

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galecto

GRI Bio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Palisade Bio

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Revolution Medicines

Soligenix

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Tharimmune

Theriva Biologics

VivoSim Labs

Longevity Health Holdings, Inc. - Common Stock

Comments

SILO Pharma

SILO Pharma (SILO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO